2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.
Biopharma Bankruptcies Still At Peak, With Little Relief in Sight Read More »
The agreement, in which Merck will pay the biotech an undisclosed initial sum to license drugs targeting a solid tumor, could net Epitopea up to $300 million down the line.
Merck and Epitopea Join Forces to Identify Unknown Tumor Antigens Read More »
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective alternative to Merck’s Welireg in renal cell carcinoma.
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data Read More »
Recently appointed HHS Secretary Robert F. Kennedy Jr. in 2018 helped bring several cases against vaccine maker Merck, alleging i2025 njury linked to its HPV shot Gardasil.
RFK Jr.-Linked Lawsuit Against Merck Suspended After Confirmation: Reuters Read More »
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for the second half of 2025.
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again Read More »
Executive coaches can help executives take their game to the next level in four key ways, from improving their self-awareness to reshaping their thinking.
Leadership Lab: Take a Cue From Athletes by Working With an Executive Coach Read More »
WhatsApp es una de las aplicaciones de mensajería más utilizadas en el mundo. Muchas personas buscan formas de rastrear un número de WhatsApp sin ser descubiertos, ya sea por seguridad, preocupación por un ser querido o control parental. Aunque no existe un método …
¿Cómo rastrear un número de WhatsApp sin que lo sepan? Read More »
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.
Site Survival: Why Clinical Research Sites Need a Lifeline Read More »
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of the industry’s top-performers are losing key market protections. Some companies are more prepared than others.
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It Read More »
The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines and psychedelic therapies could be facing very different futures under newly confirmed HHS Secretary Robert F. Kennedy, Jr., Moderna continues its downward revenue slide and Merck, Regeneron, BMS and more face strong patent headwinds.
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom Read More »
